Latent tuberculosis infection reactivation in patients with multiple sclerosis in use of disease-modifying therapies: A systematic review
- 1 October 2021
- journal article
- review article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 55, 103184
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Multiple sclerosisThe Lancet, 2018
- Infectious risk stratification in multiple sclerosis patients receiving immunotherapyAnnals of Clinical and Translational Neurology, 2017
- Multiple Sclerosis: Immunopathology and Treatment UpdateBrain Sciences, 2017
- Update on Disease-Modifying Therapies for Multiple SclerosisJournal of Investigative Medicine, 2017
- Effect of teriflunomide on QuantiFERON-TB Gold resultsMedical Microbiology and Immunology, 2016
- Central Nervous System Infections With Immunomodulatory TherapiesContinuum, 2015
- LatentMycobacterium tuberculosisInfectionNew England Journal of Medicine, 2015
- How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?Expert Review of Neurotherapeutics, 2014
- Breathlessness, night sweats, and weight loss on natalizumabThe Lancet, 2012
- Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumabJournal of Neuroimmunology, 2012